ACHL — Achilles Therapeutics Share Price
Last trade - 00:00- $99.48m
- -$166.84m
- 52
- 55
- 24
- 40
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.34 | ||
| Price to Tang. Book | 0.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.54% | ||
| Return on Equity | -25.52% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Achilles Therapeutics plc is a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- November 18th, 2020
- Public Since
- March 31st, 2021
- No. of Employees
- 242
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 40,754,227
- Address
- 245 Hammersmith Road, Gunnels Wood Road, LONDON, W6 8PW
- Web
- https://www.achillestx.com/
- Phone
- +44 2081544600
- Auditors
- KPMG LLP
Latest News for ACHL
Upcoming Events for ACHL
Achilles Therapeutics PLC Annual Shareholders Meeting
Q2 2022 Achilles Therapeutics PLC Earnings Release
Q3 2022 Achilles Therapeutics PLC Earnings Release
Similar to ACHL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
ACADIA Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 07:00 UTC, shares in Achilles Therapeutics are trading at $2.45. This share price information is delayed by 15 minutes.
Shares in Achilles Therapeutics last closed at $2.45 and the price had moved by -81.15% over the past 365 days. In terms of relative price strength the Achilles Therapeutics share price has underperformed the S&P500 Index by -80.12% over the past year.
The overall consensus recommendation for Achilles Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Achilles Therapeutics does not currently pay a dividend.
Achilles Therapeutics does not currently pay a dividend.
Achilles Therapeutics does not currently pay a dividend.
To buy shares in Achilles Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.45, shares in Achilles Therapeutics had a market capitalisation of $99.48m.
Here are the trading details for Achilles Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACHL
Based on an overall assessment of its quality, value and momentum Achilles Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Achilles Therapeutics is $16.33. That is 566.53% above the last closing price of $2.45.
Analysts covering Achilles Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.13 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Achilles Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -40.77%.
As of the last closing price of $2.45, shares in Achilles Therapeutics were trading -47.33% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Achilles Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Achilles Therapeutics' directors